Etanercept Liquid

Phase 3

Amgen Inc. (AMGN)

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

18 competitors in Rheumatoid Arthritis

Drug Information

Target Indication

Rheumatoid Arthritis

Clinical Trial

NCT00110903

Last updated: 1/23/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA2/13/2017

Lifmior

Rheumatoid arthritis; Juvenile idiopathic arthritis Psoriatic arthritis; Axial spondyloarthritis; Plaque psoriasis; Paediatric plaque psoriasis.

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

AMGN

Amgen Inc.

Biological Products, (No Diagnostic Substances)•North America•NASDAQ

Related Pipeline

PegaspargasePhase 3

Acute Lymphoblastic Leukemia

TarlatamabPhase 3

Small Cell Lung Cancer

romosozumab HCP administration with PFSPhase 3

Post-Menopausal Osteoporosis

Denosumab (AMG 162)Phase 3

Postmenopausal Osteoporosis

AMG 162 / DenosumabPhase 3

Breast Cancer

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts